Wedbush has assumed coverage of Voyager Therapeutics (NASDAQ:VYGR) with an outperform rating, highlighting the company’s ...
Wedbush upgraded Voyager Therapeutics (VYGR) to Outperform from Neutral with a price target of $11, up from $7, after ...
Key Takeaways Wedbush upgraded Snowflake as the analysts predicted that the artificial intelligence software era is ...
Wedbush would characterize demand for iPhone 16 so far since its September launch as “slightly ahead to generally in line with expectations ...
Wedbush analyst Daniel Ives keeps an Outperform rating on Microsoft (MSFT) with a $550 price target after Bloomberg reported the Federal Trade Commission opened an antitrust investigation into the ...
The EV maker’s stock gained 3.7% on Friday, leaving the shares ahead nearly 40% for the year and giving it a market value of ...
Microsoft stock was lagging its tech peers on Friday as investors reacted to news the company is facing a broad inquiry from ...
IMAX Corp.’s shares have climbed 71.2% in 2024, and analyst firm Wedbush sees more upside ahead for the high-end movie-theater operator.
Trump previously vowed to end federal electric vehicle tax credits, which are worth up to $7,500 for new zero-emission ...
Best Buy is one of the worst S&P 500 stocks Tuesday after the retailer missed quarterly earnings expectations and slashed its ...
Apple Inc.’s skeptics and bears have missed the last more than $1 trillion upward move in the stock by overlooking three key dynamics behind the story, Wedbush analysts said Friday. Apple has an ...